利德曼 (300289.SZ) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

72.7x

Market Cap

CNY 3.13B

MomentumView details →

1D Return

−3.20%

YTD Return

−15.64%

RSI (14)

49.6

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

72.7x

Market Cap

CNY 3.13B

RSI (14)

49.6

MomentumView details →

1D Return

−3.20%

YTD Return

−15.64%

ProfitabilityView details →

Gross Margin

47.75%

Net Margin

−8.09%

EBITDA Margin

11.42%

ROE (TTM)

−1.57%

ROA (TTM)

−1.46%

Asset Turnover

0.18x

GrowthView details →

Revenue YoY

−10.34%

EPS YoY

+66.75%

FCF YoY

−89.21%

Revenue CAGR 3Y

−22.68%

EPS CAGR 3Y

+71.43%

EBITDA YoY

—

EarningsView details →

EPS (Actual)

—

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Capital & dividendView details →

Debt/Equity

0.00x

Current Ratio

13.99x

Quick Ratio

12.88x

Div Yield

—

Div Rate

—

Div Growth 1Y

−50.00%

Financials snapshotView financials →

Revenue (TTM)

317.86M

Net Income (TTM)

−25.70M

Op. CF (TTM)

26.15M

Latest newsMore news →

Leadman's subsidiary Beijing Xiansheng Xiangrui Biological Products Co., Ltd. obtained clinical trial approval from the National Medical Products Administration for its recombinant serogroup B meningococcal vaccine, agreeing to conduct clinical trials to prevent epidemic cerebrospinal meningitis caused by Neisseria meningitidis serogroup B.29d ago

Leadman Biochemistry discloses cumulative litigation involving approximately 106 million yuan.36d ago

Similar companies

天元宠物301335.SZ 永和智控002795.SZ 中瑞股份301587.SZ 神开股份002278.SZ 安联锐视301042.SZ 华伍股份300095.SZ Find similar companies →

Latest newsMore news →

Leadman's subsidiary Beijing Xiansheng Xiangrui Biological Products Co., Ltd. obtained clinical trial approval from the National Medical Products Administration for its recombinant serogroup B meningococcal vaccine, agreeing to conduct clinical trials to prevent epidemic cerebrospinal meningitis caused by Neisseria meningitidis serogroup B.29d ago Leadman Biochemistry discloses cumulative litigation involving approximately 106 million yuan.36d ago